Cocrystal Pharma Commences Patient Enrollment for Hong Kong Phase 2a Study of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus

Ads

You May Also Like

Cellectar Biosciences Announces Year End 2015 Financial Results

MADISON, Wis., March 10, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused ...